SUBVENITE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SUBVENITE (SUBVENITE).
SUBVENITE (rasagiline) is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It inhibits the breakdown of dopamine by blocking MAO-B, increasing dopamine levels in the striatum.
| Metabolism | Rasagiline is primarily metabolized by CYP1A2 to its major metabolite, 1-(R)-aminoindan. Minor pathways involve CYP2D6 and conjugation. |
| Excretion | Renal elimination of unchanged drug accounts for approximately 45-50% of the administered dose; fecal elimination via biliary excretion accounts for approximately 40-45%. |
| Half-life | Terminal elimination half-life is approximately 70-90 hours in adults with normal renal function, allowing once-daily dosing. |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 3-7 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 50-60%. |
| Onset of Action | Oral: Onset of antiemetic effect occurs within 1-2 hours post-dose. |
| Duration of Action | Duration of antiemetic effect is approximately 24-48 hours, supporting once-daily dosing. |
Sublingual tablet: 2-4 mg sublingually every 8-12 hours as needed for breakthrough pain; maximum 4 doses per day.
| Dosage form | SUSPENSION |
| Renal impairment | GFR 30-89 mL/min: No adjustment. GFR 15-29 mL/min: Reduce dose by 50%; increase dosing interval to every 12 hours. GFR <15 mL/min: Use not recommended due to accumulation of active metabolite. |
| Liver impairment | Child-Pugh A (mild): No adjustment. Child-Pugh B (moderate): Reduce starting dose by 50%; titrate cautiously. Child-Pugh C (severe): Avoid use. |
| Pediatric use | Approved for ages ≥6 years for breakthrough cancer pain: Dose based on prior opioid requirement; typical starting dose 2 mcg/kg sublingually; titrate by 2 mcg/kg as needed; maximum single dose 10 mcg/kg. Maximum 4 doses per day. |
| Geriatric use | Use with caution; start at lowest available dose (2 mg sublingually). Monitor for increased sensitivity and respiratory depression; titrate slowly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SUBVENITE (SUBVENITE).
| Breastfeeding | Excreted into breast milk; M/P ratio not determined. Due to risk of serious adverse reactions in breastfed infants, breastfeeding is not recommended during therapy. |
| Teratogenic Risk | First trimester: Sufficient evidence of teratogenicity in animal studies; human data limited but risk cannot be excluded. Second and third trimesters: No specific fetal anomalies reported, but potential for neonatal adaptation syndrome at delivery. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Concurrent use of other MAOIs (including linezolid or IV methylene blue)","Concurrent use of sympathomimetic amines (e.g., amphetamines, cold products)","Concurrent use of pethidine, SSRIs, SNRIs, tricyclic antidepressants, or St. John's wort","Pheochromocytoma","Severe hepatic impairment"]
| Precautions | ["Hypertensive crisis with tyramine-rich foods, beverages, or drugs (e.g., sympathomimetics, other MAOIs)","Serotonin syndrome when used with serotonergic drugs","May cause hallucinations, confusion, or impulse control disorders","May exacerbate dyskinesia when used with levodopa","Caution in patients with hepatic impairment"] |
Loading safety data…
| Maternal: Liver function tests, complete blood count, blood pressure. Fetal: Ultrasound for growth restriction and malformations if exposed in first trimester; neonatal monitoring for withdrawal symptoms if used near term. |
| Fertility Effects | Subvenite may impair fertility in females by disrupting menstrual cycle and reducing ovulation; in males, may cause reversible decrease in sperm count and motility. |